08/04/2026
A survey conducted by Nic Hulscher and his team involving 197 cancer patients who used ivermectin and mebendazole over a six-month period reported encouraging outcomes:
* 84.4% of participants experienced some level of clinical improvement
* 32.8% showed no detectable signs of disease
* 15.6% had measurable tumor reduction
These findings align with what we’ve observed in our own work with over 9,000 cancer patients through one of the largest ivermectin-focused treatment initiatives worldwide.
Based on patient feedback over time, we’ve consistently seen around 75–80% reporting benefits. These range from tumor shrinkage and disease stabilization to, in some cases, prevention of recurrence.
Interest in ivermectin as a repurposed drug in oncology continues to grow, and further studies are likely to explore its potential role.
Kudos to Dr. Peter McCullough, Dr. Harvey Risch, and their colleagues for contributing to this ongoing discussion.
There is a growing call for the medical community to more closely examine repurposed medications like ivermectin as part of future cancer research.
